Study analysis · The lancet. Gastroenterology & hepatology · 2023
The blockbuster weight-loss drug semaglutide failed to reverse liver scarring in a groundbreaking cirrhosis trial — but it did melt liver fat and improve metabolic health.
In people with liver scarring from NASH, weekly semaglutide shots for a year did not significantly improve scarring, but they reduced liver fat and helped weight and blood sugar.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This was a randomized controlled trial, which is one of the best ways to test if a medicine works. It compared semaglutide to a placebo in people with severe liver scarring (cirrhosis). The main result was that semaglutide did not significantly improve liver scarring or inflammation, so we cannot say it fixes the liver. It did help with weight loss and blood sugar, which are important for overall health.
What’s the bottom line?
A 48-week trial tested weekly semaglutide 2.4 mg against placebo in 71 people with NASH-related cirrhosis. Semaglutide did not significantly improve liver scarring or clear NASH, but it did reduce liver fat and improve weight and blood sugar. Corrections/errata have been published; check the notices for updated information.
How strong is this study?
The study was well-designed because it was randomized and double-blind, meaning neither patients nor doctors knew who got the real medicine, which helps prevent bias. But the study was very small (only 71 people), so it may not have had enough power to detect a real difference in liver scarring. Also, the main goal was changed during the study, which can make results harder to trust.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
82 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=71)+6.0/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although the study is a randomized, double-blind, placebo-controlled trial (Level 1b), it is underpowered for its revised primary endpoint, the confidence interval for the primary outcome is wide and crosses 1 (OR 0.28, 95% CI 0.06–1.24), and the primary endpoint was not statistically significant. Therefore, this trial cannot establish that semaglutide causes improvement in liver fibrosis or NASH resolution. Significant secondary outcomes (weight loss, HbA1c, liver fat, liver enzymes) may support causal inference with caution, but they are exploratory and not adjusted for multiplicity.
Major COI
Major conflicts that significantly reduce study credibility
The study likely tests semaglutide, a Novo Nordisk product, and is sponsored by industry, but no funding or conflict-of-interest statement is provided in the excerpt. This constitutes a major potential conflict because the funder has a direct financial interest in the study drug.
Funders
Independent Analysis Safeguards
- Double-blind, placebo-controlled design
- Central randomisation via interactive web response system
- Patients, investigators, trial site staff, and sponsor remained blinded
- Outcome assessed by a central pathologist blinded to visit, patient characteristics, and treatment
- MRI scans analysed by a central imaging supplier blinded to treatment
The provided excerpt lacks a conflict-of-interest or funding statement. Semaglutide is a Novo Nordisk product, making industry funding highly likely, but the funder is not named in the text. The primary endpoint was changed from MRE to liver biopsy after protocol completion but before unblinding, which could indicate sponsor or regulatory influence. The negative result reduces concern that the study serves as marketing, but the undisclosed industry sponsorship remains a major COI concern.
Key takeaways
- 01
Primary: 11% vs 29% had liver fibrosis improvement (relative odds ratio 0.28; p=0.087; absolute difference about 18 fewer per 100 people, not statistically significant).
- 02
NASH resolution: 34% vs 21% (relative odds ratio 1.97; p=0.29; absolute difference about 13 more per 100, not statistically significant).
- 03
Liver fat ≥30% reduction: 49% vs 13% (relative odds ratio 6.58; p=0.0037; absolute difference about 36 more per 100).
- 04
Weight: mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points.
- 05
HbA1c in diabetes: -1.39% vs +0.24%; absolute difference -1.63 percentage points.
- 06
ALT drop ≥17 U: 40% vs 8%; absolute difference about 32 more per 100.
- 07
For the main liver scarring endpoint, the result was not statistically significant, so semaglutide did not clearly improve scarring; the absolute difference was about 18 fewer per 100 but could be chance.
- 08
The liver fat and metabolic improvements were statistically significant, with about 36 more per 100 achieving ≥30% liver fat reduction and an average 8.75 percentage point greater weight loss.
- 09
The trial was small and underpowered, and absolute risks for clinical outcomes like death or decompensation were not reported.
- 10
Published corrections/errata exist; check them for updated information.
Surprising findings
- Placebo numerically outperformed semaglutide on the primary endpointIt is counterintuitive that a placebo group would have more than double the rate of fibrosis improvement (29% vs 11%), even if not statistically significant. This may reflect baseline imbalance or biopsy sampling variability.
- Liver fat plummeted without fibrosis improvementMany assume reducing liver fat automatically reverses scarring; this trial shows a dramatic fat reduction (49% vs 13%) with no significant scar benefit.
- No liver decompensation despite advanced cirrhosisGLP-1s cause GI side effects and weight loss, which could be risky in cirrhosis, but no decompensating events or deaths occurred.
Practical takeaways
If you have NASH cirrhosis, don't expect semaglutide alone to reverse scarring based on this trial.
Small, underpowered phase 2; secondary endpoints improved; check published corrections/errata.
low-moderate for primary endpoint confidenceSemaglutide may still improve liver fat, weight, blood sugar, and ALT; discuss with your hepatologist.
Secondary endpoints, not clinical outcomes; GI side effects common.
moderate confidenceMonitor for GI side effects like nausea, diarrhea, vomiting if prescribed.
Most were mild-moderate and transient, but some led to dose reduction/discontinuation.
high confidenceDon't use liver enzyme improvements as proof of cirrhosis reversal.
ALT improved significantly but fibrosis did not; need biopsy or validated non-invasive tests.
moderate confidenceWhy this study matters
Primary endpoint miss: no significant fibrosis improvement
In 71 adults with NASH-related compensated cirrhosis, semaglutide 2.4 mg weekly did not significantly improve liver fibrosis by ≥1 stage without worsening NASH: 11% (5/47) vs 29% (7/24) with placebo; relative odds ratio 0.28 (95% CI 0.06–1.24; p=0.087); absolute difference about 18 fewer per 100 patients, not statistically significant. NASH resolution also did not differ significantly: 34% vs 21%; relative OR 1.97 (95% CI 0.56–7.91; p=0.29); absolute difference about 13 more per 100.
GLP-1 drugs are hyped as miracle treatments; this trial shows they may not reverse advanced liver scarring, challenging expectations for cirrhosis.
Liver fat melted, but scars stayed
Semaglutide significantly reduced liver fat: ≥30% reduction in 49% (23/47) vs 13% (3/24) with placebo; relative odds ratio 6.58 (95% CI 1.63–39.31; p=0.0037); absolute difference about 36 more per 100. MRI-PDFF estimated treatment ratio 0.67 (95% CI 0.51–0.88; p=0.0042).
It suggests liver fat and liver scarring are not the same thing; you can improve one without fixing the other, which matters for how we measure treatment success.
Weight loss was substantial
Mean relative weight change was -8.83% with semaglutide vs -0.09% with placebo; absolute treatment difference -8.75 percentage points (95% CI -12.41 to -5.09; p<0.0001). 62% on semaglutide lost ≥5% body weight and 40% lost ≥10%, vs 25% and 0% on placebo.
Weight loss is the mainstay of NASH treatment, and semaglutide delivered it even in people with cirrhosis, but we don't know if it was healthy muscle or fat loss.
Blood sugar control improved in diabetes
Among patients with type 2 diabetes, HbA1c changed by -1.39% with semaglutide vs +0.24% with placebo; absolute treatment difference -1.63 percentage points (95% CI -2.20 to -1.06; p<0.0001). 75% of trial participants had diabetes.
Diabetes worsens liver outcomes, so improving glucose control could have indirect liver benefits even if scarring didn't reverse.
Liver enzymes dropped
ALT improved significantly: estimated treatment ratio 0.76 (95% CI 0.61–0.93; p=0.0090). A clinically significant ≥17 U decrease occurred in 40% (19/47) vs 8% (2/24) with placebo; absolute difference about 32 more per 100 (p=0.0057). AST and GGT also improved.
ALT is a common liver blood test; patients may see improvements and assume scarring is reversing, but this trial shows that may not be true.
Safety: GI side effects, but no liver decompensation
Adverse events were similar overall (89% vs 79%) and serious AEs (13% vs 8%). Nausea (45% vs 17%), diarrhea (19% vs 8%), and vomiting (17% vs 0%) were more common with semaglutide. There were no decompensating events or deaths.
Cirrhosis patients are fragile; the absence of liver decompensation is reassuring, but GI side effects could hurt quality of life.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A 48-week trial tested weekly semaglutide 2.4 mg against placebo in 71 people with NASH-related cirrhosis. Semaglutide did not significantly improve liver scarring or clear NASH, but it did reduce liver fat and improve weight and blood sugar. Corrections/errata have been published; check the notices for updated information.
Research results
Primary: 11% vs 29% had liver fibrosis improvement (relative odds ratio 0.28; p=0.087; absolute difference about 18 fewer per 100 people, not statistically significant). NASH resolution: 34% vs 21% (relative odds ratio 1.97; p=0.29; absolute difference about 13 more per 100, not statistically significant). Liver fat ≥30% reduction: 49% vs 13% (relative odds ratio 6.58; p=0.0037; absolute difference about 36 more per 100). Weight: mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points. HbA1c in diabetes: -1.39% vs +0.24%; absolute difference -1.63 percentage points. ALT drop ≥17 U: 40% vs 8%; absolute difference about 32 more per 100.
What this means - more context
For the main liver scarring endpoint, the result was not statistically significant, so semaglutide did not clearly improve scarring; the absolute difference was about 18 fewer per 100 but could be chance. The liver fat and metabolic improvements were statistically significant, with about 36 more per 100 achieving ≥30% liver fat reduction and an average 8.75 percentage point greater weight loss. The trial was small and underpowered, and absolute risks for clinical outcomes like death or decompensation were not reported. Published corrections/errata exist; check them for updated information.
To investigate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo in adults with biopsy-confirmed NASH-related compensated cirrhosis.
Note: This study has published corrections/errata; readers should check the correction notices for updated information. In this 48-week, double-blind, placebo-controlled phase 2 trial of 71 adults with NASH-related compensated cirrhosis, semaglutide 2.4 mg did not significantly improve liver fibrosis by ≥1 stage without worsening NASH versus placebo: 11% (5/47) vs 29% (7/24); relative odds ratio 0.28 (95% CI 0.06–1.24; p=0.087); absolute difference about 18 fewer per 100 patients, not statistically significant. NASH resolution also did not differ significantly: 34% (16/47) vs 21% (5/24); relative odds ratio 1.97 (95% CI 0.56–7.91; p=0.29); absolute difference about 13 more per 100. Semaglutide significantly reduced liver fat (≥30% reduction: 49% vs 13%; relative odds ratio 6.58; p=0.0037; absolute difference about 36 more per 100), body weight (mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points), HbA1c in type 2 diabetes (-1.39% vs +0.24%; absolute difference -1.63 percentage points), and ALT (≥17 U decrease: 40% vs 8%; absolute difference about 32 more per 100). Gastrointestinal adverse events were more common with semaglutide; no new safety concerns or decompensating events/deaths.
Methods Used
Multinational, multicentre, randomised, double-blind, placebo-controlled phase 2 trial in 38 centres in Europe and USA. Adults with biopsy-confirmed NASH and compensated cirrhosis (Kleiner F4), BMI ≥27 kg/m², were randomised 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or visually matching placebo for 48 weeks (plus 7-week follow-up). Primary endpoint: proportion with improvement in liver fibrosis of ≥1 stage without worsening NASH on biopsy in intention-to-treat population. Stratified by presence/absence of type 2 diabetes.
Main Finding
Primary endpoint not met: no statistically significant difference in fibrosis improvement ≥1 stage without worsening NASH (11% semaglutide vs 29% placebo; relative odds ratio 0.28, 95% CI 0.06–1.24; p=0.087; absolute difference about 18 fewer per 100 patients). NASH resolution also not significant (34% vs 21%; relative odds ratio 1.97, 95% CI 0.56–7.91; p=0.29; absolute difference about 13 more per 100). Secondary endpoints favored semaglutide: ≥30% liver fat reduction (49% vs 13%; relative odds ratio 6.58, 95% CI 1.63–39.31; p=0.0037; absolute difference about 36 more per 100); weight loss (mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points); HbA1c reduction in type 2 diabetes (-1.39% vs +0.24%; absolute difference -1.63 percentage points); ALT ≥17 U decrease (40% vs 8%; absolute difference about 32 more per 100).
Confidence Level
Moderate for secondary/metabolic findings; low-moderate for the primary histological endpoint because the trial was small (71 randomised; 61 evaluable biopsies), the primary endpoint was changed during the trial from MRE to biopsy, and the study was likely underpowered for the revised endpoint. Strengths: randomised, double-blind, placebo-controlled, high completion rate.
Study Flags
Red Flags
- •Small phase 2 trial (71 randomised) likely underpowered after primary endpoint was changed from MRE to biopsy during the trial.
- •Baseline imbalance: semaglutide group had more severe fibrosis markers (higher Ishak scores, hepatic collagen, MRE, liver enzymes) than placebo, which may have biased against showing benefit.
- •Histology assessed by a single pathologist, with baseline biopsies allowed up to 12 months old; published corrections/errata exist and should be checked.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Placebo numerically outperformed semaglutide on the primary endpoint
It is counterintuitive that a placebo group would have more than double the rate of fibrosis improvement (29% vs 11%), even if not statistically significant. This may reflect baseline imbalance or biopsy sampling variability.
Practical Takeaways
If you have NASH cirrhosis, don't expect semaglutide alone to reverse scarring based on this trial.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This was a randomized controlled trial, which is one of the best ways to test if a medicine works. It compared semaglutide to a placebo in people with severe liver scarring (cirrhosis). The main result was that semaglutide did not significantly improve liver scarring or inflammation, so we cannot say it fixes the liver. It did help with weight loss and blood sugar, which are important for overall health.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Multicentre (38 centres) in Europe and USA
- Stratified by presence/absence of type 2 diabetes
Weaknesses
- Small sample size (71) and underpowered for revised primary endpoint
- Primary endpoint changed mid-trial from MRE to biopsy
- Single pathologist not blinded to time of biopsy
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A 48-week trial tested weekly semaglutide 2.4 mg against placebo in 71 people with NASH-related cirrhosis. Semaglutide did not significantly improve liver scarring or clear NASH, but it did reduce liver fat and improve weight and blood sugar. Corrections/errata have been published; check the notices for updated information.
Research results
Primary: 11% vs 29% had liver fibrosis improvement (relative odds ratio 0.28; p=0.087; absolute difference about 18 fewer per 100 people, not statistically significant). NASH resolution: 34% vs 21% (relative odds ratio 1.97; p=0.29; absolute difference about 13 more per 100, not statistically significant). Liver fat ≥30% reduction: 49% vs 13% (relative odds ratio 6.58; p=0.0037; absolute difference about 36 more per 100). Weight: mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points. HbA1c in diabetes: -1.39% vs +0.24%; absolute difference -1.63 percentage points. ALT drop ≥17 U: 40% vs 8%; absolute difference about 32 more per 100.
What this means - more context
For the main liver scarring endpoint, the result was not statistically significant, so semaglutide did not clearly improve scarring; the absolute difference was about 18 fewer per 100 but could be chance. The liver fat and metabolic improvements were statistically significant, with about 36 more per 100 achieving ≥30% liver fat reduction and an average 8.75 percentage point greater weight loss. The trial was small and underpowered, and absolute risks for clinical outcomes like death or decompensation were not reported. Published corrections/errata exist; check them for updated information.
To investigate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo in adults with biopsy-confirmed NASH-related compensated cirrhosis.
Note: This study has published corrections/errata; readers should check the correction notices for updated information. In this 48-week, double-blind, placebo-controlled phase 2 trial of 71 adults with NASH-related compensated cirrhosis, semaglutide 2.4 mg did not significantly improve liver fibrosis by ≥1 stage without worsening NASH versus placebo: 11% (5/47) vs 29% (7/24); relative odds ratio 0.28 (95% CI 0.06–1.24; p=0.087); absolute difference about 18 fewer per 100 patients, not statistically significant. NASH resolution also did not differ significantly: 34% (16/47) vs 21% (5/24); relative odds ratio 1.97 (95% CI 0.56–7.91; p=0.29); absolute difference about 13 more per 100. Semaglutide significantly reduced liver fat (≥30% reduction: 49% vs 13%; relative odds ratio 6.58; p=0.0037; absolute difference about 36 more per 100), body weight (mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points), HbA1c in type 2 diabetes (-1.39% vs +0.24%; absolute difference -1.63 percentage points), and ALT (≥17 U decrease: 40% vs 8%; absolute difference about 32 more per 100). Gastrointestinal adverse events were more common with semaglutide; no new safety concerns or decompensating events/deaths.
Methods Used
Multinational, multicentre, randomised, double-blind, placebo-controlled phase 2 trial in 38 centres in Europe and USA. Adults with biopsy-confirmed NASH and compensated cirrhosis (Kleiner F4), BMI ≥27 kg/m², were randomised 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or visually matching placebo for 48 weeks (plus 7-week follow-up). Primary endpoint: proportion with improvement in liver fibrosis of ≥1 stage without worsening NASH on biopsy in intention-to-treat population. Stratified by presence/absence of type 2 diabetes.
Main Finding
Primary endpoint not met: no statistically significant difference in fibrosis improvement ≥1 stage without worsening NASH (11% semaglutide vs 29% placebo; relative odds ratio 0.28, 95% CI 0.06–1.24; p=0.087; absolute difference about 18 fewer per 100 patients). NASH resolution also not significant (34% vs 21%; relative odds ratio 1.97, 95% CI 0.56–7.91; p=0.29; absolute difference about 13 more per 100). Secondary endpoints favored semaglutide: ≥30% liver fat reduction (49% vs 13%; relative odds ratio 6.58, 95% CI 1.63–39.31; p=0.0037; absolute difference about 36 more per 100); weight loss (mean relative change -8.83% vs -0.09%; absolute difference -8.75 percentage points); HbA1c reduction in type 2 diabetes (-1.39% vs +0.24%; absolute difference -1.63 percentage points); ALT ≥17 U decrease (40% vs 8%; absolute difference about 32 more per 100).
Confidence Level
Moderate for secondary/metabolic findings; low-moderate for the primary histological endpoint because the trial was small (71 randomised; 61 evaluable biopsies), the primary endpoint was changed during the trial from MRE to biopsy, and the study was likely underpowered for the revised endpoint. Strengths: randomised, double-blind, placebo-controlled, high completion rate.
Study Flags
Red Flags
- •Small phase 2 trial (71 randomised) likely underpowered after primary endpoint was changed from MRE to biopsy during the trial.
- •Baseline imbalance: semaglutide group had more severe fibrosis markers (higher Ishak scores, hepatic collagen, MRE, liver enzymes) than placebo, which may have biased against showing benefit.
- •Histology assessed by a single pathologist, with baseline biopsies allowed up to 12 months old; published corrections/errata exist and should be checked.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Placebo numerically outperformed semaglutide on the primary endpoint
It is counterintuitive that a placebo group would have more than double the rate of fibrosis improvement (29% vs 11%), even if not statistically significant. This may reflect baseline imbalance or biopsy sampling variability.
Practical Takeaways
If you have NASH cirrhosis, don't expect semaglutide alone to reverse scarring based on this trial.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This was a randomized controlled trial, which is one of the best ways to test if a medicine works. It compared semaglutide to a placebo in people with severe liver scarring (cirrhosis). The main result was that semaglutide did not significantly improve liver scarring or inflammation, so we cannot say it fixes the liver. It did help with weight loss and blood sugar, which are important for overall health.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Multicentre (38 centres) in Europe and USA
- Stratified by presence/absence of type 2 diabetes
Weaknesses
- Small sample size (71) and underpowered for revised primary endpoint
- Primary endpoint changed mid-trial from MRE to biopsy
- Single pathologist not blinded to time of biopsy
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was well-designed because it was randomized and double-blind, meaning neither patients nor doctors knew who got the real medicine, which helps prevent bias. But the study was very small (only 71 people), so it may not have had enough power to detect a real difference in liver scarring. Also, the main goal was changed during the study, which can make results harder to trust.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
82 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=71)+6.0/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 574 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although the study is a randomized, double-blind, placebo-controlled trial (Level 1b), it is underpowered for its revised primary endpoint, the confidence interval for the primary outcome is wide and crosses 1 (OR 0.28, 95% CI 0.06–1.24), and the primary endpoint was not statistically significant. Therefore, this trial cannot establish that semaglutide causes improvement in liver fibrosis or NASH resolution. Significant secondary outcomes (weight loss, HbA1c, liver fat, liver enzymes) may support causal inference with caution, but they are exploratory and not adjusted for multiplicity.
Major COI
Major conflicts that significantly reduce study credibility
The study likely tests semaglutide, a Novo Nordisk product, and is sponsored by industry, but no funding or conflict-of-interest statement is provided in the excerpt. This constitutes a major potential conflict because the funder has a direct financial interest in the study drug.
Funders
Independent Analysis Safeguards
- Double-blind, placebo-controlled design
- Central randomisation via interactive web response system
- Patients, investigators, trial site staff, and sponsor remained blinded
- Outcome assessed by a central pathologist blinded to visit, patient characteristics, and treatment
- MRI scans analysed by a central imaging supplier blinded to treatment
The provided excerpt lacks a conflict-of-interest or funding statement. Semaglutide is a Novo Nordisk product, making industry funding highly likely, but the funder is not named in the text. The primary endpoint was changed from MRE to liver biopsy after protocol completion but before unblinding, which could indicate sponsor or regulatory influence. The negative result reduces concern that the study serves as marketing, but the undisclosed industry sponsorship remains a major COI concern.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
11 researchersIf this is your work, this is how we attribute it on Fit Body Science. Rohit Seth Loomba is listed as the lead author.